F
Frédéric Fina
Researcher at Aix-Marseille University
Publications - 89
Citations - 3037
Frédéric Fina is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 28, co-authored 83 publications receiving 2715 citations. Previous affiliations of Frédéric Fina include Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients.
Véronique Quillien,Audrey Lavenu,Lucie Karayan-Tapon,Catherine Carpentier,Marianne Labussière,Thierry Lesimple,Olivier Chinot,Michel Wager,Jérôme Honnorat,Stephan Saikali,Frédéric Fina,Marc Sanson,Dominique Figarella-Branger +12 more
TL;DR: There is a strong need to determine the best technique for O6‐methylguanine‐DNA‐methyltranferase (MGMT) analysis, because MGMT status is currently used in clinical trials and occasionally in routine clinical practice for glioblastoma patients.
Journal ArticleDOI
Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Alexandru Saveanu,Ginette Gunz,Henry Dufour,P. Caron,Frédéric Fina,L'Houcine Ouafik,Michael D. Culler,J. P. Moreau,Alain Enjalbert,P. Jaquet +9 more
TL;DR: Data indicate that due to heterogeneous expression of SSTR2 and SSTR5 receptor subtypes, in GH-secreting tumors, a bispecific analog that can activate both receptors could achieve better control of GH hypersecretion in a larger number of acromegalic patients.
Journal ArticleDOI
Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
P. Jaquet,Alexandru Saveanu,Ginette Gunz,Frédéric Fina,Alfredo J. Zamora,Michel Grino,Michael D. Culler,J. P. Moreau,Alain Enjalbert,L'Houcine Ouafik +9 more
TL;DR: The quantitative expression of messenger ribonucleic acid for the 5 SSTR subtypes and the inhibitory effects of SRIF14; SRIF28; octreotide; the SSTR2-preferential analog, BIM-23197; and the S STR5-preferring analogs on GH and PRL secretion were analyzed, showing a highly variable ratio of the Sstr2 and SSTR5 transcripts, according to tumors.
Journal ArticleDOI
Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.
Céline Chappé,Laetitia Padovani,Laetitia Padovani,Didier Scavarda,Fabien Forest,Isabelle Nanni-Metellus,Anderson Loundou,Sandy Mercurio,Sandy Mercurio,Frédéric Fina,Gabriel Lena,Carole Colin,Carole Colin,Dominique Figarella-Branger,Dominique Figarella-Branger +14 more
TL;DR: DNT shared with PXA and GG, BRAFV600E mutation and/or CD34 expression, which represent molecular markers for these tumors, and it is recommended that all DNTs be searched for, especially the non‐specific forms.
Journal ArticleDOI
Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo.
L'Houcine Ouafik,Samantha Sauze,Françoise Boudouresque,Olivier Chinot,Christine Delfino,Frédéric Fina,Vincent Vuaroqueaux,Christophe Dussert,Jacqueline Palmari,H. Dufour,François Grisoli,Pierre Casellas,Nils Brünner,Pierre-Marie Martin +13 more
TL;DR: It is demonstrated that a polyclonal antibody specific to AM, blocks the binding of the hormone to its cellular receptors and decreases by 33% the growth of U87 glioblastoma cells in vitro, and that inhibition of the action of AM (produced by tumor cells) may suppress tumor growth in vivo.